<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529902</url>
  </required_header>
  <id_info>
    <org_study_id>2019A010961-3</org_study_id>
    <secondary_id>75N95019C00057</secondary_id>
    <nct_id>NCT04529902</nct_id>
  </id_info>
  <brief_title>Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) TNFi vs Abatacept</brief_title>
  <acronym>DREAM</acronym>
  <official_title>Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - Tumor Necrosis Factor Inhibitors vs Abatacept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset&#xD;
      between patients treated with medications that target specific metabolic pathways and&#xD;
      patients treated with alternative medications for the same indication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham&#xD;
      and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical&#xD;
      and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National&#xD;
      Institute on Aging (NIA) intramural research program. This study aims to evaluate the&#xD;
      comparative risk of dementia/Alzheimer's disease onset between patients treated with&#xD;
      medications that target specific metabolic pathways and patients treated with alternative&#xD;
      medications for the same indication using healthcare claims data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to dementia onset</measure>
    <time_frame>Through study completion (a median of 253 days)</time_frame>
    <description>Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Alzheimer's disease onset Time to Alzheimer's disease onset</measure>
    <time_frame>Through study completion (a median of 253 days)</time_frame>
    <description>Time to Alzheimer's disease onset. Please refer to uploaded protocol for full definition due to size limitations.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">66026</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tumor necrosis factor inhibitors</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tumor Necrosis Factor Inhibitors</intervention_name>
    <description>TNFi claim is used as the reference group.</description>
    <arm_group_label>Tumor necrosis factor inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Abatacept claim is used as the exposure group.</description>
    <arm_group_label>Abatacept</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve a new user, parallel group, cohort study design comparing TNF&#xD;
        inhibitors to abatacept. The patients will be required to have continuous enrollment during&#xD;
        the baseline period of 355 days before initiation of TNF inhibitors or abatacept (cohort&#xD;
        entry date). Follow-up for the outcome (incident dementia), begins the day after drug&#xD;
        initiation for analyses 1, 3, and 4 and 180 days after drug initiation for analysis 2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Please see&#xD;
        https://docs.google.com/spreadsheets/d/11fIivBOto16Gyb_1xM8AXNHn-EC4v7TiLzCjpbbXF0Q/edit?us&#xD;
        p=sharing or Appendix A for full code and algorithm definitions.&#xD;
&#xD;
        Medicare timeframe: 2007 to 2017 (end of data availability).&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  1. No prior use of tumor necrosis factor inhibitors or abatacept anytime prior to&#xD;
             cohort entry date&#xD;
&#xD;
          -  2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to&#xD;
             and including cohort entry date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Prior history of dementia measured anytime prior to cohort entry date&#xD;
&#xD;
          -  2. No prior history of rheumatoid arthritis recorded in the 365 days prior to cohort&#xD;
             entry date&#xD;
&#xD;
          -  3. Prior history of nursing home admission in the 365 days prior to the cohort entry&#xD;
             date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rishi J Desai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madhav Thambisetty, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Rishi J. Desai</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tumor Necrosis Factor Inhibitors</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT04529902/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

